Which has stronger earnings & valuation, HIK or HCM?

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hikma Pharmaceuticals £3.42B 0.98 £353.21M £176.00 9.17 HUTCHMED £549.12M 3.32 -£52.98M £2.00 104.79

Hikma Pharmaceuticals (HIK) Competitors

GBX 1,614.57 +3.57 (+0.22%)

As of 08:30 AM Eastern

Compare

HIK vs. DPH, INDV, HCM, VEC, and ERGO

Should you buy Hikma Pharmaceuticals stock or one of its competitors? Hikma Pharmaceuticals's main competitors and comparable companies include Dechra Pharmaceuticals (DPH), Indivior (INDV), HUTCHMED (HCM), Vectura Group (VEC), and Ergomed (ERGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Hikma Pharmaceuticals compare to Dechra Pharmaceuticals?

Hikma Pharmaceuticals (LON:HIK) and Dechra Pharmaceuticals (LON:DPH) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Hikma Pharmaceuticals has a beta of 0.662, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Hikma Pharmaceuticals' average media sentiment score of 0.20 beat Dechra Pharmaceuticals' score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
Dechra Pharmaceuticals	Neutral

Hikma Pharmaceuticals has a net margin of 11.31% compared to Dechra Pharmaceuticals' net margin of -3.66%. Hikma Pharmaceuticals' return on equity of 15.05% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are held by institutional investors. 22.3% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,085.83, suggesting a potential upside of 29.19%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hikma Pharmaceuticals has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	0.98	£353.21M	£176.00	9.17
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 5.1%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Hikma Pharmaceuticals beats Dechra Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Indivior?

Hikma Pharmaceuticals (LON:HIK) and Indivior (LON:INDV) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Hikma Pharmaceuticals has a beta of 0.662, meaning that its share price is 34% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Hikma Pharmaceuticals presently has a consensus target price of GBX 2,085.83, suggesting a potential upside of 29.19%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Hikma Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 5.1%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 86.0% of Indivior shares are held by institutional investors. 22.3% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 3.4% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Indivior had 3 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 3 mentions for Indivior and 0 mentions for Hikma Pharmaceuticals. Indivior's average media sentiment score of 0.40 beat Hikma Pharmaceuticals' score of 0.20 indicating that Indivior is being referred to more favorably in the news media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
Indivior	Neutral

Hikma Pharmaceuticals has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	0.98	£353.21M	£176.00	9.17
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

Indivior has a net margin of 11.44% compared to Hikma Pharmaceuticals' net margin of 11.31%. Hikma Pharmaceuticals' return on equity of 15.05% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
Indivior	11.44%	-23.90%	2.37%

Summary

Hikma Pharmaceuticals beats Indivior on 12 of the 18 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to HUTCHMED?

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.7% of HUTCHMED shares are owned by institutional investors. 22.3% of Hikma Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 11.31%. HUTCHMED's return on equity of 36.88% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
HUTCHMED	163.84%	36.88%	-5.90%

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	0.98	£353.21M	£176.00	9.17
HUTCHMED	£549.12M	3.32	-£52.98M	£2.00	104.79

Hikma Pharmaceuticals has a beta of 0.662, indicating that its share price is 34% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, indicating that its share price is 57% less volatile than the broader market.

In the previous week, HUTCHMED had 1 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for Hikma Pharmaceuticals. Hikma Pharmaceuticals' average media sentiment score of 0.20 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
HUTCHMED	Neutral

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,085.83, indicating a potential upside of 29.19%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Hikma Pharmaceuticals beats HUTCHMED on 11 of the 16 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Vectura Group?

Hikma Pharmaceuticals (LON:HIK) and Vectura Group (LON:VEC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. 22.3% of Hikma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hikma Pharmaceuticals' average media sentiment score of 0.20 beat Vectura Group's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
Vectura Group	Neutral

Hikma Pharmaceuticals has higher revenue and earnings than Vectura Group. Vectura Group is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	0.98	£353.21M	£176.00	9.17
Vectura Group	£190.60M	0.00	N/A	£20.10	N/A

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,085.83, suggesting a potential upside of 29.19%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Hikma Pharmaceuticals is more favorable than Vectura Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vectura Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hikma Pharmaceuticals has a net margin of 11.31% compared to Vectura Group's net margin of 0.00%. Hikma Pharmaceuticals' return on equity of 15.05% beat Vectura Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
Vectura Group	N/A	N/A	N/A

Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 5.1%. Vectura Group pays an annual dividend of GBX 38 per share. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. Vectura Group pays out 189.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Hikma Pharmaceuticals beats Vectura Group on 14 of the 14 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Ergomed?

Hikma Pharmaceuticals (LON:HIK) and Ergomed (LON:ERGO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Hikma Pharmaceuticals has higher revenue and earnings than Ergomed. Ergomed is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	0.98	£353.21M	£176.00	9.17
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Hikma Pharmaceuticals has a beta of 0.662, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Hikma Pharmaceuticals presently has a consensus price target of GBX 2,085.83, indicating a potential upside of 29.19%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Hikma Pharmaceuticals is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hikma Pharmaceuticals' average media sentiment score of 0.20 beat Ergomed's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
Ergomed	Neutral

Hikma Pharmaceuticals has a net margin of 11.31% compared to Ergomed's net margin of 9.87%. Ergomed's return on equity of 18.08% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
Ergomed	9.87%	18.08%	10.16%

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 22.3% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 18.2% of Ergomed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Hikma Pharmaceuticals beats Ergomed on 9 of the 14 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIK vs. The Competition

Export

Metric	Hikma Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£3.34B	£12.48B	£7.25B	£2.90B
Dividend Yield	4.02%	2.63%	2.53%	6.22%
P/E Ratio	9.17	789.78	275.10	366.54
Price / Sales	0.98	946.12	685.34	90,165.57
Price / Cash	8.34	15.08	28.04	27.89
Price / Book	1.57	10.57	10.49	6.33
Net Income	£353.21M	£2.82B	£3.49B	£5.89B
7 Day Performance	3.70%	0.45%	0.76%	1.28%
1 Month Performance	-1.31%	-1.18%	-2.84%	0.24%
1 Year Performance	-1.13%	4.22%	16.64%	19.71%

Hikma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIK Hikma Pharmaceuticals	4.6174 of 5 stars	GBX 1,614.57 +0.2%	GBX 2,085.83 +29.2%	-0.7%	£3.34B	£3.42B	9.17	9,500
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+0.0%	£1.93B	£1.40B	N/A	1,000	Gap Up High Trading Volume
HCM HUTCHMED	N/A	GBX 201 flat	N/A	-14.9%	£1.75B	£549.12M	100.50	1,760	Gap Up
VEC Vectura Group	N/A	N/A	N/A	N/A	£1.01B	£190.60M	8.20	9,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HIK) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hikma Pharmaceuticals (HIK) Competitors

HIK vs. DPH, INDV, HCM, VEC, and ERGO

How does Hikma Pharmaceuticals compare to Dechra Pharmaceuticals?

Summary

How does Hikma Pharmaceuticals compare to Indivior?

Summary

How does Hikma Pharmaceuticals compare to HUTCHMED?

Summary

How does Hikma Pharmaceuticals compare to Vectura Group?

Summary

How does Hikma Pharmaceuticals compare to Ergomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIK vs. The Competition

Hikma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hikma Pharmaceuticals (HIK) Competitors

HIK vs. DPH, INDV, HCM, VEC, and ERGO

How does Hikma Pharmaceuticals compare to Dechra Pharmaceuticals?

Which has more volatility and risk, HIK or DPH?

Does the media favor HIK or DPH?

Is HIK or DPH more profitable?

Do institutionals and insiders believe in HIK or DPH?

Do analysts recommend HIK or DPH?

Which has higher earnings and valuation, HIK or DPH?

Is HIK or DPH a better dividend stock?

Summary

How does Hikma Pharmaceuticals compare to Indivior?

Which has more volatility and risk, HIK or INDV?

Do analysts prefer HIK or INDV?

Is HIK or INDV a better dividend stock?

Do insiders and institutionals hold more shares of HIK or INDV?

Does the media prefer HIK or INDV?

Which has better valuation and earnings, HIK or INDV?

Is HIK or INDV more profitable?

Summary

How does Hikma Pharmaceuticals compare to HUTCHMED?

Do institutionals and insiders have more ownership in HIK or HCM?

Is HIK or HCM more profitable?

Which has stronger earnings & valuation, HIK or HCM?

Which has more risk & volatility, HIK or HCM?

Does the media favor HIK or HCM?

Do analysts recommend HIK or HCM?

Summary

How does Hikma Pharmaceuticals compare to Vectura Group?

Do insiders and institutionals hold more shares of HIK or VEC?

Does the media refer more to HIK or VEC?

Which has stronger valuation & earnings, HIK or VEC?

Do analysts prefer HIK or VEC?

Is HIK or VEC more profitable?

Is HIK or VEC a better dividend stock?

Summary

How does Hikma Pharmaceuticals compare to Ergomed?

Which has preferable earnings & valuation, HIK or ERGO?

Which has more volatility and risk, HIK or ERGO?

Do analysts prefer HIK or ERGO?

Does the media refer more to HIK or ERGO?

Is HIK or ERGO more profitable?

Do institutionals and insiders believe in HIK or ERGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIK vs. The Competition

Hikma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools